3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
6
Thoracic
3
Breast
3
Tumor-Agnostic
2
Gastrointestinal
2
Dermatologic
2
Classical hematology
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
CNS
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Interventions
pembrolizumab
157
Nivolumab
132
Ipilimumab
77
Cyclophosphamide
46
Specimen Handling
44
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
28
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
21
fludarabine phosphate
20
dabrafenib
20
atezolizumab
20
Radiotherapy
20
Opdualag
19
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
aldesleukin
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lenvatinib
11
Bevacizumab
11
lifileucel
10
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Tretinoin
×
Dermatologic
×
1 year
×
Clear all
NCT04303169
2025-10-27
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
146 enrolled
NCT04305041
2025-08-29
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
100 enrolled